Analyst Price Targets — XENE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 10, 2026 2:17 pm | Benjamin Burnett | Wells Fargo | $69.00 | $56.44 | TheFly | Xenon Pharmaceuticals price target raised to $69 from $68 at Wells Fargo |
| May 8, 2026 1:46 pm | Serge Belanger | Needham | $78.00 | $56.55 | TheFly | Xenon Pharmaceuticals price target lowered to $78 from $80 at Needham |
| March 10, 2026 8:35 am | — | Deutsche Bank | $90.00 | $60.61 | TheFly | Xenon Pharmaceuticals price target raised to $90 from $56 at Deutsche Bank |
| March 9, 2026 7:53 pm | — | RBC Capital | $80.00 | $62.76 | TheFly | Xenon Pharmaceuticals price target raised to $80 from $59 at RBC Capital |
| March 9, 2026 7:52 pm | Andrew Tsai | Jefferies | $100.00 | $62.76 | StreetInsider | Xenon Pharmaceuticals (XENE) PT Raised to $100 at Jefferies |
| March 9, 2026 6:47 pm | Yatin Suneja | Guggenheim | $90.00 | $62.76 | StreetInsider | Xenon Pharmaceuticals (XENE) PT Raised to $90 at Guggenheim |
| March 9, 2026 4:20 pm | — | Robert W. Baird | $97.00 | $62.76 | StreetInsider | Xenon Pharmaceuticals (XENE) PT Raised to $97 at Baird |
| March 9, 2026 4:20 pm | — | Morgan Stanley | $97.00 | $62.76 | StreetInsider | Xenon Pharmaceuticals (XENE) PT Raised to $97 at Baird |
| March 9, 2026 1:30 pm | Paul Matteis | Stifel Nicolaus | $89.00 | $61.58 | StreetInsider | Xenon Pharmaceuticals (XENE) PT Raised to $89 at Stifel |
| March 9, 2026 1:18 pm | Andrew Tsai | Jefferies | $65.00 | $61.56 | StreetInsider | Jefferies Reiterates Buy Rating on Xenon Pharmaceuticals (XENE): "We see a +50-75% stock move" |
Latest News for XENE
Xenon Pharmaceuticals (XENE) is transitioning into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform and strong Phase 3 epilepsy data. XENE's lead candidate, azetukalner, showed robust efficacy in refractory focal onset seizures and is progressing toward a Q3 2026 NDA filing. The company has a cash runway through 2029, supporting ongoing Phase 3 trials in MDD, bipolar…
VANCOUVER, British Columbia and BOSTON, MA, July 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to four new non-officer employees consisting of an aggregate of 20,200 share…
XENE's shares climb 22% in six months as azetukalner delivers strong phase III epilepsy data and advances across multiple late-stage studies.
VANCOUVER, British Columbia and BOSTON, MA, May 29, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to 10 new non-officer employees consisting of an aggregate of 32,750 share options…
VANCOUVER, British Columbia and BOSTON, MA, May 29, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to 10 new non-officer employees consisting of an aggregate of 32,750 share options…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for XENE.
U.S. House Trading
No House trades found for XENE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.